Pharmaceutical Monitoring of a Case of Pulmonary Hemorrhage with Coagulation Dysfunction in a 680 g Extremely Low Birth Weight Infant at 25+1 Weeks Gestation
DOI:
https://doi.org/10.56147/jbhs.3.2.137Keywords:
- Extremely low birth weight infant,
- Neonatal pulmonary hemorrhage,
- Coagulation disorders,
- Human fibrinogen
Abstract
Objective: To conduct pharmaceutical monitoring for a case of Pulmonary Hemorrhage (PH) accompanied by coagulation dysfunction in a 680 g Extremely Low Birth Weight (ELBW) infant at 25+1 weeks of gestation and to provide a reference for the clinical treatment of PH in ELBW infants.
Methods: The patient's bleeding treatment regimen was optimized. Interventions included the use of tranexamic acid for antifibrinolytic hemostasis, transfusion of fresh frozen plasma (9 times) and cryoprecipitate (4 times), vitamin K₁ supplementation to improve coagulation function, subcutaneous injection of heparin calcium for anticoagulation (2 times) and administration of human fibrinogen to elevate fibrinogen levels (2 times).
Results: The patient's bleeding was successfully controlled. Following two administrations of human fibrinogen, the infant's coagulation function and Platelet count (PLT) were essentially restored to normal.
Conclusion: When coagulation dysfunction occurs in ELBW infants, vigilance for the onset of pulmonary hemorrhage is crucial. The use of fibrinogen-containing interventions can improve coagulation function and mitigate risk factors for pulmonary hemorrhage in these patients.
Downloads
References
Welde MA, Sanford CB, Mangum M, Paschal C, Jnah AJ (2021) Pulmonary hemorrhage in the neonate. Neonatal Netw 40: 295-304.
Lee J, Lee CYM, Naiduvaje K, et al. (2023) Trends in neonatal mortality and morbidity in Very-Low-Birth-Weight (VLBW) infants over a decade: Singapore national cohort study. Pediatr Neonatol 64: 585-595.
Zhang ZZ, Yang Y, Sun Y, et al. (2025) Clinical characteristics and influencing factors of pulmonary hemorrhage in extremely low birth weight infants. Zhongguo Fu You Jian Kang Yan Jiu 36: 70-77.
Aziz A, Ohlsson A (2012) Surfactant for pulmonary haemorrhage in neonates. Cochrane Database Syst Rev: CD005254.
Usemann J, Garten L, Bührer C, Dame C, Cremer M (2017) Fresh frozen plasma transfusion: A risk factor for pulmonary hemorrhage in extremely low birth weight infants? J Perinat Med 45: 627-633.
Hansen TN, Corbet A (2005) Avery’s Diseases of the Newborn (8th ed.). Saunders: Philadelphia, USA: 634-647.
Chen D, Wang M, Wang X, et al. (2017) High-risk factors and clinical characteristics of massive pulmonary hemorrhage in infants with extremely low birth weight. Zhongguo Dang Dai Er Ke Za Zhi 19: 54-58.
Cao ZL, Pan JJ, Chen XQ, et al. (2022) Risk factors for pulmonary hemorrhage in very low birth weight infants and their clinical outcomes. Zhongguo Dang Dai Er Ke Za Zhi 24: 1117-1123.
Ahmad KA, Bennett MM, Ahmad SF, et al. (2019) Morbidity and mortality with early pulmonary haemorrhage in preterm neonates. Arch Dis Child Fetal Neonatal Ed 104: F63-F68.
Li J, Xia H, Ye L, et al. (2021) Exploring prediction model and survival strategies for pulmonary hemorrhage in premature infants: A single-center, retrospective study. Transl Pediatr 10: 1324-1332.
Zhu W, Zou YS, Wu Y, et al. (2023) Analysis of factors influencing the clinical outcome of pulmonary hemorrhage in very low birth weight infants. Lin Chuang Er Ke Za Zhi 41: 658-664.
Song YF, Li J (2021) Progress in the treatment of patent ductus arteriosus in extremely low birth weight infants. Guo Ji Er Ke Xue Za Zhi 48: 828-832.
Motta M, Del Vecchio A, Perrone B, et al. (2014) Fresh frozen plasma use in the NICU: A prospective, observational, multicentred study. Arch Dis Child Fetal Neonatal Ed 99: F303-F308.
Raban MS, Harrison MC (2015) Fresh frozen plasma use in a neonatal unit in South Africa. J Trop Pediatr 61: 266-271.
Ferreira CH, Carmona F, Martinez FE (2014) Prevalence, risk factors and outcomes associated with pulmonary hemorrhage in newborns. J Pediatr 90: 316-322.
Liu K, Yang XH, Li JD (2024) A case of severe fibrinogen reduction caused by hemocoagulase from Deinagkistrodon acutus in the treatment of gastrointestinal bleeding. Jiangxi Yi Yao 59: 994-996.
Miao HQ, Su DL, Chen XX (2022) Pharmaceutical monitoring practice and literature analysis of a case of coagulation disorder induced by hemocoagulase for injection (Deinagkistrodon acutus). Zhongguo Yao Ye 31: 119-122.
Qi M, Zhang Y, Yang SB, et al. (2023) Clinical characteristics and high-risk factors of pulmonary hemorrhage in extremely preterm infants. Zhonghua Xin Sheng Er Ke Za Zhi 38: 200-204.
Liu G, Chen Q, Chu ZJ, et al. (2021) Research progress on the clinical application of human fibrinogen. Zhongguo Shu Xue Za Zhi 34: 935-938.
Rong ZR, Tan Z (2024) Efficacy of tranexamic acid injection combined with lyophilized human fibrinogen in treating traumatic coagulopathy and its effect on coagulation function. Lin Chuang He Li Yong Yao 17: 94-97.
Dahlbäck B (2023) Natural anticoagulant discovery, the gift that keeps on giving: Finding FV-short. J Thromb Haemost 21: 716-727.
Zuo X, Zhang H, Zhou T, et al. (2020) Spheroids of endothelial cells and vascular smooth muscle cells promote cell migration in hyaluronic acid and fibrinogen composite hydrogels. Research: 8970480.
